Bever CT[au] - Search Results

Year	Number of Results
1955	1
1956	1
1981	1
1982	2
1983	2
1984	1
1985	4
1986	1
1988	2
1989	3
1990	2
1991	3
1992	1
1993	2
1994	3
1995	2
1996	3
1997	2
1998	7
1999	3
2001	7
2002	1
2003	2
2005	2
2006	2
2007	2
2008	4
2009	5
2010	5
2011	4
2012	4
2013	3
2014	2
2015	6
2016	6
2017	4
2018	1
2019	3
2020	2
2022	0

1

Practice improvement requires more than guidelines and quality measures.

Sigsbee B, Bever CT Jr, Jones LK Jr. Sigsbee B, et al. Among authors: bever ct jr. Neurology. 2016 Jan 12;86(2):188-93. doi: 10.1212/WNL.0000000000002116. Epub 2015 Oct 30. Neurology. 2016. PMID: 26519541 Review.

2

Sustained-release fampridine for multiple sclerosis.

Bever CT, Judge SI. Bever CT, et al. Expert Opin Investig Drugs. 2009 Jul;18(7):1013-24. doi: 10.1517/13543780903002082. Expert Opin Investig Drugs. 2009. PMID: 19548855 Review.

3

SIRT1 and NAD+ precursors: Therapeutic targets in multiple sclerosis a review.

Nimmagadda VK, Makar TK, Chandrasekaran K, Sagi AR, Ray J, Russell JW, Bever CT Jr. Nimmagadda VK, et al. Among authors: bever ct jr. J Neuroimmunol. 2017 Mar 15;304:29-34. doi: 10.1016/j.jneuroim.2016.07.007. Epub 2016 Jul 17. J Neuroimmunol. 2017. PMID: 27474445 Free PMC article. Review.

4

Cell-based delivery of brain-derived neurotrophic factor in experimental allergic encephalomyelitis.

Makar TK, Nimmagadda VK, Trisler D, Bever CT Jr. Makar TK, et al. Among authors: bever ct jr. J Interferon Cytokine Res. 2014 Aug;34(8):641-7. doi: 10.1089/jir.2013.0160. Epub 2014 Mar 6. J Interferon Cytokine Res. 2014. PMID: 24601738 Review.

5

Matrix metalloproteinases in multiple sclerosis: targets of therapy or markers of injury?

Bever CT Jr, Rosenberg GA. Bever CT Jr, et al. Neurology. 1999 Oct 22;53(7):1380-1. doi: 10.1212/wnl.53.7.1380. Neurology. 1999. PMID: 10534237 Review. No abstract available.

6

Potassium channel blockers and openers as CNS neurologic therapeutic agents.

Judge SI, Smith PJ, Stewart PE, Bever CT Jr. Judge SI, et al. Among authors: bever ct jr. Recent Pat CNS Drug Discov. 2007 Nov;2(3):200-28. doi: 10.2174/157488907782411765. Recent Pat CNS Drug Discov. 2007. PMID: 18221232 Review.

7

Voltage-gated potassium channels in multiple sclerosis: Overview and new implications for treatment of central nervous system inflammation and degeneration.

Judge SI, Lee JM, Bever CT Jr, Hoffman PM. Judge SI, et al. Among authors: bever ct jr. J Rehabil Res Dev. 2006 Jan-Feb;43(1):111-22. doi: 10.1682/jrrd.2004.09.0116. J Rehabil Res Dev. 2006. PMID: 16847777 Free article. Review.

8

Potassium channel blockers in multiple sclerosis: neuronal Kv channels and effects of symptomatic treatment.

Judge SI, Bever CT Jr. Judge SI, et al. Among authors: bever ct jr. Pharmacol Ther. 2006 Jul;111(1):224-59. doi: 10.1016/j.pharmthera.2005.10.006. Epub 2006 Feb 9. Pharmacol Ther. 2006. PMID: 16472864 Review.

9

Summary of comprehensive systematic review: Rehabilitation in multiple sclerosis: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology.

Haselkorn JK, Hughes C, Rae-Grant A, Henson LJ, Bever CT, Lo AC, Brown TR, Kraft GH, Getchius T, Gronseth G, Armstrong MJ, Narayanaswami P. Haselkorn JK, et al. Among authors: bever ct. Neurology. 2015 Nov 24;85(21):1896-903. doi: 10.1212/WNL.0000000000002146. Neurology. 2015. PMID: 26598432 Free PMC article. Review.

10

Robot-Assisted Arm Training in Chronic Stroke: Addition of Transition-to-Task Practice.

Conroy SS, Wittenberg GF, Krebs HI, Zhan M, Bever CT, Whitall J. Conroy SS, et al. Among authors: bever ct. Neurorehabil Neural Repair. 2019 Sep;33(9):751-761. doi: 10.1177/1545968319862558. Epub 2019 Jul 22. Neurorehabil Neural Repair. 2019. PMID: 31328671 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results